Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental therapy in Hodgkin's disease.

A Engert1, C Pohl, V Diehl

  • 1Medizinische Universitätsklinik I, Universität zu Köln, Germany.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|September 1, 1992
PubMed
Summary

Targeting Hodgkin/Reed-Sternberg cells with immunotoxins and bispecific antibodies shows promise for Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bovine milk and milk protein- promotor or inhibitor of bacterial biofilm formation at the tooth surface?

BMC oral health·2025
Same author

Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2020
Same author

Asylum-Seeking Children with Medical Complexity and Rare Diseases in a Tertiary Hospital in Switzerland.

Journal of immigrant and minority health·2020
Same author

Corrigendum to "Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial": Annals of Oncology 2012; 23: 1818-1825.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Hodgkin/Reed-Sternberg (H-RS) cells in Hodgkin's lymphoma express unique lymphoid activation markers, CD25 and CD30.
  • These markers are present on a limited number of normal cells, making them ideal therapeutic targets.

Purpose of the Study:

  • To explore novel experimental strategies for targeting H-RS cells in Hodgkin's lymphoma.
  • To evaluate the efficacy of immunotoxins and bispecific antibody constructs in preclinical models.

Main Methods:

  • Development of immunotoxins by linking monoclonal antibodies against CD25/CD30 to deglycosylated ricin A-chain.
  • Utilizing bispecific constructs to convert prodrugs into toxic agents specifically at the H-RS cell surface.
  • Employing monoclonal antibodies for active immunotherapy approaches.

Main Results:

  • Immunotoxins demonstrated significant tumor destruction, eliminating up to 60% of small H-RS tumors in mice.
  • The most potent immunotoxin is advancing to clinical trials.
  • Bispecific constructs and active immunotherapy represent alternative experimental strategies.

Conclusions:

  • Targeting CD25 and CD30 on H-RS cells is a viable strategy for Hodgkin's lymphoma treatment.
  • Immunotoxins show significant preclinical efficacy and are progressing to human trials.
  • Further research into bispecific constructs and active immunotherapy may offer additional therapeutic options.

Related Experiment Videos